6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2024

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

On November 20, 2024, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), issued a press release announcing that Enlivex’s board of directors approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 20, 2024

Exhibit 99.1

Enlivex Adopts Bitcoin Treasury Reserve Strategy

Nes-Ziona, Israel, November 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company’s Board of Directors approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy.

“As demand for Bitcoin has grown, together with its rising acceptance as a recognized medium of exchange, we believe that Bitcoin will serve the Company as a strong and diversifying treasury reserve asset,” said Oren Hershkovitz, CEO of Enlivex. “With the recent approvals of Bitcoin ETFs and growing support from institutional investors, we believe that Bitcoin can provide the Company with a potential functional store of value and an inflation hedge to standard currencies.”

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.

Safe Harbor Statement: This press release containsforward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,”“will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,”“intends,” “estimates,” “suggests,” “has the potential to” and other words of similarmeaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinicalexperiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM^ programs. All such forward-looking statementsare made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned thatforward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risksthat Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail,may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of theseproducts for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or anyactivity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials inanimals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The developmentof any products using the ALLOCETRA^TM^ product line could also be affected by a number of other factors, including unexpectedsafety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceuticalindustry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitorsand other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental,technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’smost recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained inthis press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-lookingstatements, except as required under applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO

Enlivex Therapeutics, Ltd.

shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT

Dave Gentry, CEO

RedChip Companies Inc.

1-407-644-4256

ENLV@redchip.com